1Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis[J]. Chest,2000,117 ( Suppl 2 ):380s.
2Anthonisen NR, Manfreda J, Warren CP,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease[J]. Ann Intern Med, 1987,106:196
3Stass H, Dalhoff A, Kubitza D,et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8 - methoxy guinolone, administered to healthy subjects[J]. Antimicrob Agents Chemother, 1998,42:2060.
4Richarx W. Moxifloxacin clinical pharmacology[J]. Clin Drug,1999,17(5) :365.
5Andrews J, Honeybourue D, Jevons G, et al. Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single 400mg oral dose[C]. 38th Int Conf Antimicrob Agents Chemother, 1998:Abstract A29.
6Bauer T, Landen H. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis[J]. Clin Drug Invest,2002,22(10):641.
7Chodosh S,De Abate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis[J]. Respir Med,2000 Jan,94(1):17.
